Stulc Tomáš, Ceška Richard, Gotto Antonio M
3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, U Nemocnice 1, CZ 128 21, Praha 2 / Prague, Czech Republic.
Weill Cornell Medical College, New York, 1305 York Avenue, Y-807, New York, NY, 10021, USA.
Curr Atheroscler Rep. 2015 Dec;17(12):69. doi: 10.1007/s11883-015-0552-3.
Muscle problems and other adverse symptoms associated with statin use are frequent reasons for non-adherence and discontinuation of statin therapy, which results in inadequate control of hyperlipidemia and increased cardiovascular risk. However, most patients who experience adverse symptoms during statin use are able to tolerate at least some degree of statin therapy. Given the profound cardiovascular benefits derived from statins, an adequate practical approach to statin intolerance is, therefore, of great clinical importance. Statin intolerance can be defined as the occurrence of myalgia or other adverse symptoms that are attributed to statin therapy and that lead to its discontinuation. In reality, these symptoms are actually unrelated to statin use in many patients, especially in those with atypical presentations following long periods of treatment. Thus, the first step in approaching patients with adverse symptoms during the course of statin therapy is identification of those patients for whom true statin intolerance is unlikely, since most of these patients would probably be capable of tolerating adequate statin therapy. In patients with statin intolerance, an altered dosing regimen of very low doses of statins should be attempted and, if tolerated, should gradually be increased to achieve the highest tolerable doses. In addition, other lipid-lowering drugs may be needed, either in combination with statins, or alone, if statins are not tolerated at all. Stringent control of other risk factors can aid in reducing cardiovascular risk if attaining lipid treatment goals proves difficult.
与他汀类药物使用相关的肌肉问题及其他不良症状,是导致不坚持服用和停用他汀类药物治疗的常见原因,这会致使高脂血症控制不佳并增加心血管疾病风险。然而,大多数在服用他汀类药物期间出现不良症状的患者,至少能够耐受一定程度的他汀类药物治疗。鉴于他汀类药物能带来显著的心血管益处,因此,针对他汀类药物不耐受制定切实可行的应对方法具有重大临床意义。他汀类药物不耐受可定义为出现归因于他汀类药物治疗且导致停药的肌痛或其他不良症状。实际上,在许多患者中,尤其是那些经过长期治疗后出现非典型症状的患者,这些症状与他汀类药物的使用并无实际关联。所以,对于在他汀类药物治疗过程中出现不良症状的患者,首要步骤是识别出那些不太可能存在真正他汀类药物不耐受的患者,因为这些患者中的大多数或许能够耐受足够剂量的他汀类药物治疗。对于他汀类药物不耐受的患者,应尝试采用极低剂量的他汀类药物调整给药方案,若能耐受,则应逐渐增加剂量以达到可耐受的最高剂量。此外,如果完全不能耐受他汀类药物,则可能需要联用其他降脂药物或单独使用其他降脂药物。如果难以实现血脂治疗目标,严格控制其他危险因素有助于降低心血管疾病风险。